Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens.
Microbiotix, Inc.
| Year | Rank |
|---|---|
| 2020 | 1st |
| 2019 | 2nd |
| 2018 | 2nd |
| 2017 | 1st |
| 2016 | 1st |
| 2015 | 1st |
| 2014 | 2nd |
| 2013 | 1st |
As a testament to our innovation, Microbiotix has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies.
The Company's lead therapeutic compound, MBX-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). MBX-400 has successfully completed Phase 1 clinical testing.